Nina JEHANNO
Head of Nuclear Medicine
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Background [18F]FDG-PET/CT images play a key role in the management of patients with Non-Small Cell Lung Cancer (NSCLC). However, in these scans, the focus is always on the detected tumors and on their characteristics, neglecting information from other organs or tissues. Purpose To investigate whether the mean brain FDG uptake (SUVmean brain ) is associated with overall survival (OS) in metastatic NSCLC patients. Materials and Methods This retrospective study included metastatic NSCLC patients who underwent pre-treatment [18F]FDG-PET/CT scans between 2010 and 2023. Clinical and biological data, tumor radiomic features, and SUVmean brain were collected. The ability of these features to predict OS was evaluated using univariable and multivariable Cox regression models. The correlation between SUVmean brain and clinical/imaging/blood biomarkers was investigated using Spearman correlation coefficients (rS). Results Patients were chronologically divided into a discovery (n = 234, mean age 64 years ± 11 [SD], 135 male) and test set (n = 146, mean age 66 years ± 11, 83 male). In the discovery set, univariable analysis showed that high SUVmean brain (≥ median) was associated with longer OS (HR = 0.83, 95% CI 0.76-0.92, P < .001). SUVmean brain was significantly lower in patients who died within one year compared to those who were still alive ( P < .001). In multivariable analysis, SUVmean brain remained an independent prognostic factor for OS (HR, 0.88; 95% CI: 0.80, 0.98; P = .02), which was confirmed in the test set ( P < .001). SUVmean brain was independent of the radiomic features quantifying tumor involvement (|rS| < 0.24, n = 380 patients) and significantly correlated but complementary to several blood biomarkers including CRP (rS = -0.37, n = 110 patients). Conclusion Low brain metabolic activity was associated with increased mortality in metastatic NSCLC patients. SUVmean brain was an independent prognostic factor that could contribute to patient stratification, although its interpretation requires further investigation.
Year:
2025
Purpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a third-generation ALK inhibitor, were identified (SACHA national registry and/or in the institution). cfDNA was analyzed at relapse for nine patients and sequentially for five patients (blood/bone marrow plasma) by performing whole-genome sequencing library construction followed by ALK -targeted ddPCR of the hotspot mutations [F1174L, R1275Q, and I1170N; variant allele fraction (VAF) detection limit 0.1%] and whole-exome sequencing (WES) to evaluate disease burden and clonal evolution, following comparison with tumor/germline WES. Results: Overall response rate to lorlatinib was 33% (CI, 13%–59%), with response observed in 6/10 cases without versus 0/8 cases with MYCN amplification (MNA). ALK VAFs correlated with the overall clinical disease status, with a VAF 30%) at progression. Importantly, sequential ALK ddPCR detected relapse earlier than clinical imaging. cfDNA WES revealed new SNVs, not seen in the primary tumor, in all instances of disease progression after lorlatinib treatment, indicating clonal evolution, including alterations in genes linked to tumor aggressivity ( TP53 ) or novel targets ( EGFR ). Gene pathway analysis revealed an enrichment for genes targeting cell differentiation in emerging clones, and cell adhesion in persistent clones. Evidence of clonal hematopoiesis could be observed in follow-up samples. Conclusions: We demonstrate the clinical utility of combining ALK cfDNA ddPCR for disease monitoring and cfDNA WES for the study of clonal evolution and resistance mechanisms in patients with neuroblastoma receiving ALK -targeted therapy.
Year:
2024
Purpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a third-generation ALK inhibitor, were identified (SACHA national registry and/or in the institution). cfDNA was analyzed at relapse for nine patients and sequentially for five patients (blood/bone marrow plasma) by performing whole-genome sequencing library construction followed by ALK -targeted ddPCR of the hotspot mutations [F1174L, R1275Q, and I1170N; variant allele fraction (VAF) detection limit 0.1%] and whole-exome sequencing (WES) to evaluate disease burden and clonal evolution, following comparison with tumor/germline WES. Results: Overall response rate to lorlatinib was 33% (CI, 13%–59%), with response observed in 6/10 cases without versus 0/8 cases with MYCN amplification (MNA). ALK VAFs correlated with the overall clinical disease status, with a VAF 30%) at progression. Importantly, sequential ALK ddPCR detected relapse earlier than clinical imaging. cfDNA WES revealed new SNVs, not seen in the primary tumor, in all instances of disease progression after lorlatinib treatment, indicating clonal evolution, including alterations in genes linked to tumor aggressivity ( TP53 ) or novel targets ( EGFR ). Gene pathway analysis revealed an enrichment for genes targeting cell differentiation in emerging clones, and cell adhesion in persistent clones. Evidence of clonal hematopoiesis could be observed in follow-up samples. Conclusions: We demonstrate the clinical utility of combining ALK cfDNA ddPCR for disease monitoring and cfDNA WES for the study of clonal evolution and resistance mechanisms in patients with neuroblastoma receiving ALK -targeted therapy.
Year:
2024
Purpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a third-generation ALK inhibitor, were identified (SACHA national registry and/or in the institution). cfDNA was analyzed at relapse for nine patients and sequentially for five patients (blood/bone marrow plasma) by performing whole-genome sequencing library construction followed by ALK-targeted ddPCR of the hotspot mutations [F1174L, R1275Q, and I1170N; variant allele fraction (VAF) detection limit 0.1%] and whole-exome sequencing (WES) to evaluate disease burden and clonal evolution, following comparison with tumor/germline WES. Results: Overall response rate to lorlatinib was 33% (CI, 13%–59%), with response observed in 6/10 cases without versus 0/8 cases with MYCN amplification (MNA). ALK VAFs correlated with the overall clinical disease status, with a VAF < 0.1% in clinical remission, versus higher VAFs (>30%) at progression. Importantly, sequential ALK ddPCR detected relapse earlier than clinical imaging. cfDNA WES revealed new SNVs, not seen in the primary tumor, in all instances of disease progression after lorlatinib treatment, indicating clonal evolution, including alterations in genes linked to tumor aggressivity (TP53) or novel targets (EGFR). Gene pathway analysis revealed an enrichment for genes targeting cell differentiation in emerging clones, and cell adhesion in persistent clones. Evidence of clonal hematopoiesis could be observed in follow-up samples. Conclusions: We demonstrate the clinical utility of combining ALK cfDNA ddPCR for disease monitoring and cfDNA WES for the study of clonal evolution and resistance mechanisms in patients with neuroblastoma receiving ALK-targeted therapy.
Year:
2024
Collaborators (6)
Ivan Bieche
Université Paris Cité
Nicolas ANDRE
Professor
Aix-Marseille Université Faculté de Medecine
Sylvain BAULANDE
Head
Institut Curie
Lalith kumar Shiyam Sundar
W2 Professor: Digital Transformation in Radiology
Ludwig-Maximilians-Universität München
Irene Buvat
CNRS Délégation Ile-de-France Sud
Gudrun Schleiermacher
PSL Research University
Make your next move.
Prepare your application
Review drafts before you send them.